Soliris Comprehensive Study by Category (Plasma Exchange, Plasma Infusion), Indication (Atypical Hemolytic Uremic Syndrome (aHUS), Paroxysmal Nocturnal Hemoglobinuria (PNH), Generalized Myasthenia Gravis (gMG)), Distribution (Online Third-Party Websites, Retail Pharmacies, Hospital Dispensaries) Players and Region - Global Market Outlook to 2026

Name: Soliris Comprehensive Study by Category (Plasma Exchange, Plasma Infusion), Indication (Atypical Hemolytic Uremic Syndrome (aHUS), Paroxysmal Nocturnal Hemoglobinuria (PNH), Generalized Myasthenia Gravis (gMG)), Distribution (Online Third-Party Websites, Retail Pharmacies, Hospital Dispensaries) Players and Region - Global Market Outlook to 2026
Brand: AMA Research
SKU: 177281
Price: 3450 USD
Availability: InStock
Rating: 4.5 (19 reviews)

Soliris Market by XX Submarkets | Forecast Years 2022-2027

Summary
Market Segments
Table of Content
List of Table & Figures
Players Profiled

Summary

Soliris Market Scope

Soliris (eculizumab) is a humanised, Fc-engineered (reduced effector function), IgG2/4 hybrid monoclonal antibody that inhibits the action of human complement factor C5. Eculizumab's action allows it to effectively block the terminal complement system's pro-inflammatory and cytolytic effects, both of which are important contributors in the pathogenesis of the uncommon haemolytic illness paroxysmal nocturnal haemoglobinuria (PNH). Soliris' antibody therapy has emerged as a key example of a possible therapeutic molecule that was originally created for a variety of common inflammatory illnesses (rheumatoid arthritis, lupus, etc.) but is now widely utilised as a first-in-class complement inhibitor in the rare disease arena.

The Soliris market study is segmented and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Soliris market throughout the predicted period.

Alexion Pharmaceuticals Inc. (United States) are some of the key players that are part of study coverage.

About Approach

The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview

AMA Research has segmented the market of Global Soliris market by Type, Application and Region.

On the basis of geography, the market of Soliris has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 23rd October, 2017 � Alexion Pharma Received FDA Approval for its Soliris (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG). The Approval was Followed by a Series of Clinical Trails Presenting the Efficiency of the Medication.

Market Trend

Growing Healthcare Infrastructure Doe to Rising Government Expenditure

Market Drivers

Prevalence of Atypical Hemolytic Uremic Syndrome (aHUS)
High Investments in Pharmaceutical Research & Development

Opportunities

Increasing Demand Across Emerging Regions

Restraints

Regulatory Approval
Side Effects and Adverse Rection

Challenges

Market Penetration across New Regions

Key Target Audience

Pharmaceutical Manufactures, New Entrants and Investors, Pharmaceutical Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Market Segments

Report Objectives / Segmentation Covered

By Category

Plasma Exchange
Plasma Infusion

By Indication

Atypical Hemolytic Uremic Syndrome (aHUS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Generalized Myasthenia Gravis (gMG)

By Distribution

Online Third-Party Websites
Retail Pharmacies
Hospital Dispensaries

By Regions

South America
- Brazil
- Argentina
- Rest of South America
Asia Pacific
- China
- Japan
- India
- South Korea
- Taiwan
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- Italy
- United Kingdom
- Netherlands
- Rest of Europe
MEA
- Middle East
- Africa
North America
- United States
- Canada
- Mexico

Table of Content

List of Tables & Figures

List of Tables

List of Figures

Figure 1. Porters Five Forces
Figure 2. Supply/Value Chain
Figure 3. PESTEL analysis
Figure 4. Global Soliris: by Category USD Million (2015-2020)
Figure 5. Global Soliris: by Indication USD Million (2015-2020)
Figure 6. Global Soliris: by Distribution USD Million (2015-2020)
Figure 7. South America Soliris Share (%), by Country
Figure 8. Asia Pacific Soliris Share (%), by Country
Figure 9. Europe Soliris Share (%), by Country
Figure 10. MEA Soliris Share (%), by Country
Figure 11. North America Soliris Share (%), by Country
Figure 12. Global Soliris share by Players 2020 (%)
Figure 13. BCG Matrix for key Companies
Figure 14. Alexion Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
Figure 15. Alexion Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
Figure 16. Global Soliris: by Category USD Million (2021-2026)
Figure 17. Global Soliris: by Indication USD Million (2021-2026)
Figure 18. Global Soliris: by Distribution USD Million (2021-2026)
Figure 19. South America Soliris Share (%), by Country
Figure 20. Asia Pacific Soliris Share (%), by Country
Figure 21. Europe Soliris Share (%), by Country
Figure 22. MEA Soliris Share (%), by Country
Figure 23. North America Soliris Share (%), by Country

Companies Mentioned

List of companies from research coverage that are profiled in the study

Alexion Pharmaceuticals Inc. (United States)

Select User Access Type

Single User
$ 3450
Corporate User
$ 6500

Key Highlights of Report

Jul 2021 201 Pages 67 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing

Check Discount Now

Global Soliris Market Quantitative research analysis

Global Soliris Market Qualitative Industry Analysis

DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?

"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Soliris Market?

Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Soliris Market Report?

Have a Query? Click Here